Spero Therapeutics Inc [SPRO] stock is trading at $2.50, up 17.37%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SPRO shares have gain 258.17% over the last week, with a monthly amount glided 279.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spero Therapeutics Inc [NASDAQ: SPRO] stock has seen the most recent analyst activity on December 20, 2024, when Evercore ISI downgraded its rating to a In-line but kept the price target unchanged to $5 for it. Previously, Evercore ISI upgraded its rating to Outperform on September 23, 2022, and elevated its price target to $8. On October 01, 2021, downgrade downgraded it’s rating to Perform. H.C. Wainwright reiterated its Buy rating and increased its price target to $40 on January 22, 2021. Berenberg initiated its recommendation with a Buy and recommended $47 as its price target on December 16, 2020. In a note dated November 05, 2019, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $28 to $35.
Spero Therapeutics Inc [SPRO] stock has fluctuated between $0.51 and $2.48 over the past year. Spero Therapeutics Inc [NASDAQ: SPRO] shares were valued at $2.50 at the most recent close of the market.
Analyzing the SPRO fundamentals
Spero Therapeutics Inc [NASDAQ:SPRO] reported sales of 28.30M for the trailing twelve months, which represents a growth of 21.57%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -2.13%, Pretax Profit Margin comes in at -1.61%, and Net Profit Margin reading is -1.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.99 and Total Capital is -1.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.30 points at the first support level, and at 2.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.75, and for the 2nd resistance point, it is at 3.00.
Ratios To Look Out For
For context, Spero Therapeutics Inc’s Current Ratio is 2.56. Further, the Quick Ratio stands at 2.56, while the Cash Ratio is 1.68. Considering the valuation of this stock, the price to sales ratio is 4.94, the price to book ratio is 4.13.
Transactions by insiders
Recent insider trading involved Keutzer Timothy, Chief Operating Officer, that happened on Feb 05 ’25 when 56537.0 shares were sold. CFO & CBO, Rajavelu Esther completed a deal on Feb 05 ’25 to sell 20689.0 shares. Meanwhile, CEO & President Shukla Sath sold 0.16 million shares on Feb 05 ’25.
